- The
R&D program will focus on the proprietary Lexaria DehydraTECH delivery
technology with the purpose of enhancing it further
- Results
could contribute to new patent filings in the future; in addition, the
program will examine more extensively the way DehydraTECH-enabled CBD
outperforms generic CBD
- Lexaria-designed
nanotech enhancements will also be included in the program
Biotechnology company and drug delivery platform
innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)is
launching its largest cannabinoid research and development program to date. The
program consists of 11 separate animal studies, according to a company press
release (http://ibn.fm/xidEM).
The Lexaria in vitro study design was conceptualized six
months ago. Laboratory test articles have been produced and meet or exceed
required quality control thresholds. The program has moved on to the implementation
stage, which includes testing for a variety of performance-enhancing variations
of the company’s DehydraTECH.
The DehydraTECH trademarked delivery technology is patented
for cannabidiol (CBD) and tetrahydrocannabinoid (THC). The technology has a
wide scope of applications, with evidence gathered separately of an ability to
cross the blood-brain barrier, which could lead to applications related to
nervous system conditions like Alzheimer’s disease.
Through the research, Lexaria aims to enhance the
DehydraTECH drug delivery platform even further, with optimization enhancement
designed to improve the platform’s performance in next-generation formulations
currently under development.
As per the official Lexaria announcement, the research and
development program could contribute to additional patent filings in the
future. Thus, the company has limited information about the study’s design for
the time being. The primary aim of the research, however, is to determine the
mechanisms by which DehydraTECH-enabled CBD outperforms generic CBD – a fact
that has already been established through multiple trials.
DehydraTECH and the other Lexaria technologies are already
disrupting the cannabis edibles industry. These developments reduce the
undesirable taste of CBD products, eliminate the need for the addition of
sweeteners (simplifying the creation of sugar-free options), increase
absorption rates and reduce the time of positive effect onset.
Lexaria-designed nanotech enhancements will also be included
among the research and development program subjects. In the beginning of 2018,
Lexaria evaluated a number of nanotech emulsions for use with DehydraTECH.
These nano emulsions are expected to be tested in combination with the
DehydraTECH delivery system for the first time ever.
Various nanotech solutions are already available on the
market. No other company, however, has come up with a combination of nano
emulsions and a drug delivery platform that’s patented for use with
cannabinoids. Lexaria representatives believe that the combination enhances the
individual performance characteristics of both technologies.
DehydraTECH is a disruptive delivery technology platform
that promotes healthier ingestion methods and lower dosages, while increasing
overall effectiveness of lipophilic active molecules. Lexaria Bioscience Corp.
has multiple patents pending in over 40 countries and already has patents
granted in the U.S. and Australia for the utilization of its signature
DehydraTECH technology. The technology increases intestinal absorption rates,
allowing for more rapid delivery to the bloodstream of various orally
administered bioactive compounds, such as cannabinoids, vitamins and
non-steroid anti-inflammatory drugs.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
